Table 1.

Summary of mitochondrial ultrastructural changes of axons within the basal, middle, and apical turns of the osseous spiral lamina after various treatment cycles of cisplatin

Base mito/axon	Treatment	Saline	1st cycle	2nd cycle	3rd cycle
	Saline		0.0022	0.0011	0.0003
	1st cycle	0.0022		0.3797	0.0349
	2nd cycle	0.0011	0.3797		0.1185
	3rd cycle	0.0003	0.0349	0.1185
Base mito health	Treatment	Saline	1st cycle	2nd cycle	3rd cycle
	Saline		0.0483	0.0014	0.0003
	1st cycle	0.0483		0.0176	0.0014
	2nd cycle	0.0014	0.0176		0.0735
	3rd cycle	0.0003	0.0014	0.0735
Base mito S.A.	Treatment	Saline	1st cycle	2nd cycle	3rd cycle
	saline		0.708	0.0046	0.0103
	1st cycle	0.708		0.0046	0.0133
	2nd cycle	0.0046	0.0046		0.2924
	3rd cycle	0.0103	0.0133	0.2924
Middle mito/axon	Treatment	Saline	1st cycle	2nd cycle	3rd cycle
	Saline		0.638	0.1328	0.1328
	1st cycle	0.638		0.2042	0.1328
	2nd cycle	0.1328	0.2042		0.6526
	3rd cycle	0.1328	0.1328	0.6526
Middle mito health	Treatment	Saline	1st cycle	2nd cycle	3rd cycle
	Saline		0.0075	< 0.0001	< 0.0001
	1st cycle	0.0075		< 0.0001	< 0.0001
	2nd cycle	< 0.0001	< 0.0001		0.0011
	3rd cycle	< 0.0001	< 0.0001	0.0011
Middle mito S.A.	Treatment	saline	1st cycle	2nd cycle	3rd cycle
	saline		0.06	< 0.0001	< 0.0001
	1st cycle	0.06		0.0002	0.0002
	2nd cycle	< 0.0001	0.0002		0.7362
	3rd cycle	< 0.0001	0.0002	0.7362
Apex mito/axon	Treatment	Saline	1st cycle	2nd cycle	3rd cycle
	Saline		0.5167	0.1525	0.1148
	1st cycle	0.5167		0.3178	0.1525
	2nd cycle	0.1525	0.3178		0.4791
	3rd cycle	0.1148	0.1525	0.4791
Apex mito health	Treatment	Saline	1st cycle	2nd cycle	3rd cycle
	saline		0.0395	< 0.0001	< 0.0001
	1st cycle	0.0395		0.0001	< 0.0001
	2nd cycle	< 0.0001	0.0001		0.0026
	3rd cycle	< 0.0001	< 0.0001	0.0026
Apex mito S.A.	Treatment	Saline	1st cycle	2nd cycle	3rd cycle
	Saline		0.8751	0.087	0.5154
	1st cycle	0.8751		0.087	0.5154
	2nd cycle	0.087	0.087		0.2219
	3rd cycle	0.5154	0.5154	0.2219

Linear mixed-effect models were used and determined that there were significant changes to the presence of mitochondria per axon, the morphometric health score of each mitochondria, and the cross-sectional surface area of each mitochondria in each turn of the cochlea after three different treatment cycles of cisplatin. Bold values indicate the comparisons to the saline- and cisplatin-treated groups that reached statistical difference; p < 0.05

S.A. cross-sectional surface area